Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia

Canadian Journal of Clinical Pharmacology

Volumn 7, Issue 3, 2000, Pages 144-154

  Perreault, Sylvie ^a,b   Levinton, Carey ^c   Le Lorier, Jacques ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Faculty of Pharmacy ^*

Author keywords

Cost; Dose response; Efficacy; HMG CoA reductase inhibitors

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCREENING;

EID: 0033711230     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (128)

1. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I: Reduction in incidence of coronary heart disease
2. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
3. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-age men with dyslipidemia
4. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
5. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
6. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program
7. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
8. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
10. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
11. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
12. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
13. Reductase inhibitor monotherapy and stroke prevention
14. Cholesterol lowering with statin drugs, risk of stroke, and total mortality
15. Screening asymptomatic adults for cardiac risk factors: The serum cholesterol level
16. Cholesterol screening in asymptomatic adults, revisited
17. Serum lipid screening to identify high-risk individuals for coronary death: The results of the lipid research clinics prevalence cohort
18. Costs and health consequences of cholesterol screening for asymptomatic older Americans
19. A head to head comparison of the cost-effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemta
20. Comparison of efficacy and cost among lipid-lowering agents in patients with primary hypercholesterolemia
21. Treating hyperlipidemia for the primary prevention of coronary disease: Are higher doses of HMG-CoA reductase inhibitors cost-effective?
22. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
23. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?
24. Combining estimates of effect size
25. Fixed effects models
26. Random effects models
27. Selection of end points in economic evaluations of coronary heart disease interventions
28. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose response study
29. Treatment of primary hypercholesterolemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: A double blind comparative study
30. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II
31. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group
32. A controlled trial of pravastatin vs probucol in the treatment of primary hypercholesterolemia
33. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia
34. A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia
35. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II)
36. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia
37. Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol
38. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia
39. Efficacy and safety of pravastatin in hypertensive hypercholesterolaemic patients on antihypertensive drug therapy
40. Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The finnish multicenter study
41. Cholesterol lowering in the elderly
42. Effects of pravastatin in patients with serum total cholesterol levels from 52 to 78 mmol/L (200 to 300 mg/dL) plus two additional atherosclerotic risk factors
43. Combination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary report on safety
44. Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia
45. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins
46. Fluvastatin and niacin in hypercholesterolemia: A preliminary report on gender differences in efficacy
47. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database
48. Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels
49. Simvastatin and cholestyramine in the long term treatment of hypercholesterolaemia
50. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia
51. Comparaison de l'efficacite et de la tolerance de la simvastatine et du bezafibrate dans le traitement des hypercholesterolemies
52. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine
53. Efficacy and safety of pravastatin In the long-term treatment of elderly patients with hypercholesterolemia
54. Cholesterol reduction intervention study (CRIS)
55. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations
56. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
57. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
58. A multicenter, double-blind, one-year study comparIng safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
59. The efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
60. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: Results of a randomized, double-masked study
61. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitors
62. Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia
63. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolemia. The Simvastatin-Fluvastatin Study Group
64. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients
65. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia
66. Efficacy of a low dose-range of fluvastatin (XU62-320) in the treatment of primary hypercholesterolemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group
67. Fluvastatin reduces levels of plasma apo B-containing particles and Increases those of LpA-1
68. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia
69. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia
70. Treatment of primary hypercholesterolemia: Fluvastatin versus bezafibrate
71. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia
72. A multicenter comparative trial of lovastatin and pravastatin In the treatment of hypercholesterolemia
73. Expanded Clinical Evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
74. Expanded clinical evaluation of lovastatin (EXCEL) study: Design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia
75. A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia
76. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia
77. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia A multicenter study. The Lovastatin Study Group II
78. Lovastatin (Mevinolin) in the treatment of heterozygous familial hylercholesterolemia
79. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: Different effects on lipoprotein profiles
80. Comparison of the effects on quality of life and of efficacy and tolerability of lovastatin versus pravastatin
81. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group
82. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (Multicountry Comparative Study)
83. Simvastatin versus pravastatin: Efficacy and tolerability In patients with primary hypercholesterolemia
84. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia
85. Treating hypercholesterolaemia with HMG-CoA reductase inhibitors: A direct comparison of simvastatin and pravastatin
86. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemia subjects. A double blind test
87. Once daily pravastatin in patients with primary hypercholesterolemia: A dose-response study
88. Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia. The European Study Group
89. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. The European Study Group
90. Pravastatin and risk factor modification in patients with moderate primary hyperlipidemia
91. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia. The israeli experience
92. Treatment of familial hypercholesterolaemia: A controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels
93. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
94. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia
95. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia
96. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once daily versus twice daffy dosing
97. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I
98. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study
99. Dose-response of simvastatin in primary hypercholesterolemia
100. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects
101. Simvastatin in severe hypercholesterolemia: A placebo controlled trial
102. Effect of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia
103. Safety, tolerability, and efficacy of simvastatin and fenofibrate - A multicenter study. Simvastatin-Fenofibrate Study Group
104. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia
105. Successful management of primary hypercholesterolemia with simvastatin and low dose colestipol
106. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS)
107. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Anteroma Study (MAAS)
108. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosderosis Intervention Trial
109. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events
110. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I)
111. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC II)
112. A population-based primary preventive trial of the effect of LDL loweing on atherosclerotic progression on carotid and femoral arteries
113. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
114. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. The Post-Coronary Artery Bypass Graft Trial Investigators
115. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction
116. Three-year follow-up of the Oxford Cholesterol Study: Assessment of the efficacy and safety of simvastatin in preparation for a large mortality study
117. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia
118. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease
119. Cost-effectiveness of assessment and management of risk factors
120. Lipid lowering therapy in low-risk patients
121. Discontinuation of antihyperlipidemic drugs - Do rates reported in clinical trials reflect rates in primary care settings
122. Persistence of use of lipid-lowering medications. A cross-national study
123. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
124. The interaction of diltiazem with lovastatin and pravastatin
125. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone
126. Pravastatin: Interaction with oral anticoagulant